Maxcyte vs Seer
Maxcyte is the larger business, with $33.0m of revenue in fiscal 2025 against $16.6m for Seer (2.0 times as much). Seer grew faster (17.0% against -14.5%). Maxcyte kept more of each dollar of sales as profit: a net margin of -135.1% against -444.0%. Maxcyte carries less debt relative to equity (0.0% against 0.0%).
| Latest fiscal year | MaxcyteMXCT, 2025 | SeerSEER, 2025 |
|---|---|---|
| Revenue | $33.0m | $16.6m |
| Revenue growth | -14.5% | 17.0% |
| Net income | −$44.6m | −$73.6m |
| Operating margin | -157.1% | -470.5% |
| Net margin | -135.1% | -444.0% |
| Return on equity | -23.6% | -25.1% |
| Free cash flow | −$36.2m | −$46.2m |
| Cash | $20.1m | $47.3m |
| Total debt | $0 | $0 |
| Debt to equity | 0.0% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 91 | — |
| Market value | $150m | $94.7m |
| Price vs our value range | — | — |
| Moat score | 30 (Weak) | 22 (Weak) |
| Insider trades, 12 months | 0 buys, 1 sales | 0 buys, 7 sales |